14 results about "Neuroblastoma" patented technology

This disclosure provides compounds of formula (I) or pharmaceutically acceptable salts thereof, methods for preparing the same, and their use in the treatment and / or diagnosis of cancers such as neuroblastoma, prostate cancer, pancreatic cancer, leukemia, osteosarcoma, hepatoblastoma, lung cancer, colon cancer, breast cancer, skin cancer, thyroid cancer, and / or rhabdoid cancer. JPEG2026522940000099.jpg50170

This invention discloses a polycyclic pyrimidine compound and its uses. The invention provides a polycyclic pyrimidine compound of formula (I), its solvate, a pharmaceutically acceptable salt thereof, a solvate of its pharmaceutically acceptable salt, its tautomer, or its stereoisomer. The compound provided by this invention exhibits good degradation activity against CDK9 and good inhibitory activity against neuroblastoma.

The present application relates to the field of clinical laboratory medicine technology, in particular to a neuroblastoma and catecholamine-related tumor diagnosis kit and its application. The kit contains key components for detecting high vanillylmandelic acid and vanillylmandelic acid in urine, including isotope internal standard, specific chromatographic column, optimized mobile phase and sample pretreatment material. The detection method using the kit optimizes the collection, preservation and pretreatment process of instant urine samples, and combines the liquid chromatography-tandem mass spectrometry (LC-MS / MS) analysis conditions designed for low concentration and complex matrix samples to realize the rapid and accurate quantification of trace HVA and VMA in urine. It overcomes the shortcomings of traditional 24-hour urine detection method such as large trauma, long cycle and poor accuracy, and provides an efficient and reliable solution for non-invasive, early diagnosis and postoperative efficacy monitoring of neuroblastoma and other catecholamine-related tumors, which has important clinical application value.

The invention belongs to the technical field of bioinformatics and medical detection, and particularly relates to a marker combination for neuroblastoma (NB) noninvasive risk level grading, a prediction model, a prediction method and application thereof. The marker combination is used for determining the sex, determining whether the month age is greater than 18 months, determining whether plasma MYCN is amplified, determining whether tumors are metastatic, and determining the content of neuron-specific enolase and lactic dehydrogenase; a machine learning algorithm is used for constructing an NB noninvasive risk degree grading prediction model, the comprehensive performance of the random forest model is optimal, the area value under a subject working characteristic curve reaches 0.956, the sensitivity is 92.9%, the specificity is 82.1%, the accuracy rate is 87.5%, the Kappa value is 0.75, the F1 score is 0.881, and NB middle and low risk patients and NB high risk patients can be effectively distinguished; the NB non-invasive risk level grading prediction model constructed by the invention can quickly, accurately and non-invasively perform NB risk level grading, and has a relatively good clinical application value.

The application relates to a dihydropyridine small-molecule compound and a preparation method and application thereof in preparing a drug for treating neuroblastoma, and belongs to the technical field of drug preparation. The application discloses a dihydropyridine small-molecule compound, a structural formula of which is as shown in the description, which can be used for preparing a drug for treating neuroblastoma with high ALDH18A1 expression, can effectively solve the problems of poor water solubility of YG1702, low inhibition rate of neuroblastoma and other drug application problems, and has a good application prospect.

The application discloses a urine collection and analysis device for early diagnosis of neuroblastoma. The urine collection and analysis device comprises a collector for collecting instant urine of a patient, a valve pipe is installed through the collector, a centrifugal tank is clamped through the valve pipe, a negative pressure delivery pipe for absorbing centrifugal supernatant is connected through the centrifugal tank, a first negative pressure pump is installed on the negative pressure delivery pipe, the other side of the negative pressure delivery pipe is connected with a precipitation tank, and the precipitation tank is connected with a detection liquid storage tank through a negative pressure delivery hose. A sample distribution pipe is installed below the detection liquid storage tank, an automatic sampler is arranged below the sample distribution pipe, a plurality of samples prepared by the automatic sampler are sequentially conveyed to a chromatography control module and a mass spectrum detection module for rapid detection and analysis. The urine collection and analysis device can quickly collect, process and detect and analyze urine samples, so that neuroblastoma can be accurately diagnosed in a short time, and the diagnosis efficiency is improved.

The present application belongs to the technical field of molecular medicine, and relates to a probe, a marker combination and a prediction method for non-invasive risk grading of neuroblastoma. The probe UUU-DZ-tFNA can detect UDG in vitro, cells, living bodies and plasma exosomes, and it is proved that UDG in plasma exosomes is closely related to the risk grading of NB. The plasma exosomes of NB patients are collected MYCN Whether to amplify, whether the tumor is metastatic, neuron-specific enolase content, lactate dehydrogenase content and plasma exosome UDG content are integrated, and a NB non-invasive risk grading prediction model is established through a machine learning algorithm. The optimal risk grading model is a neural network model. The area under the receiver operating characteristic curve of the combined model is improved by 5.2% compared with the optimal prediction result of the combined prediction model of the single clinical index, and the sensitivity and specificity are significantly improved. The present application has key clinical values for accurate grading of NB children, individualized treatment plan formulation and efficacy monitoring.

The application discloses a small molecule degrading agent of aryl formamides and application thereof, and has a structure shown in general formula I or a pharmaceutically acceptable salt, an isotopically labeled compound thereof. The compound of the application has a targeted degradation activity on MYC protein, and has a significant proliferation inhibiting activity on various solid tumor cells such as neuroblastoma and rhabdomyosarcoma. The compound of the application can be used for preparing a degrading agent targeting MYC protein, and can also be used for preparing a drug for treating diseases related to MYC gene amplification, fusion, mutation, expression imbalance, conformational change and function abnormality.

The present invention relates to new ligands of the follicle stimulating hormone (FSH) receptor for use in the diagnosis and treatment of neuroblastoma.

The application relates to application of nilotinib in preparation of anti-neuroblastoma drugs, and discloses a novel signal axis driving neuroblastoma progression: USP39-KLF1-SNARE-Golgi diffusion, and finds a new use of nilotinib in preparation of anti-neuroblastoma drugs. The application finds that nilotinib can effectively destroy the protein interaction between USP39 and KLF1. The destruction leads to the decrease of KLF1 protein stability, the inhibition of the transcription activity of KLF1, the down-regulation of the expression of VAMP3 / VAMP8, the weakening of the SNARE complex function, the reversal of the Golgi diffusion phenotype, and the slowing down of the growth of neuroblastoma. Nilotinib is a marketed drug, and has clear human safety data, so the clinical transformation can be accelerated.

This application provides a system, method, and terminal for predicting the risk of bone metastasis in neuroblastoma. By acquiring laboratory test data from multiple children with neuroblastoma and constructing internal training sets, internal validation sets, external validation sets, and external test sets, a target neuroblastoma bone metastasis risk prediction model is built. Based on the target laboratory test data of the target neuroblastoma children, the system predicts the bone metastasis risk value and risk classification results for the target neuroblastoma children. This allows for timely early warning of disease changes in the early stages, reminding children and their families to seek medical attention as soon as possible. It also assists medical staff in making medical decisions and provides diagnostic evidence, solving the technical problems of limited early disease warning, high technical requirements, poor applicability, and poor safety associated with existing imaging techniques for detecting neuroblastoma bone metastasis.

This application relates to the fields of biomedicine and nuclear medicine, specifically disclosing a GD2-targeted therapy probe and its radioimmunotherapy application. It aims to address the limitations of existing probes in simultaneously achieving radionuclide labeling efficiency and antibody targeting activity, and their limited efficacy against relapsed / refractory neuroblastoma and minimal residual disease. This probe uses a hu3F8 antibody as the targeting carrier and Nota and DOTA as chelating agents to respectively match… 64 Cu、 177 Lu, a single antibody molecule coupled with 3-5 chelating agent molecules. This application also discloses a precise preparation method for the probe and its application in GD2-positive tumor PET imaging, radioimmunotherapy, SPECT monitoring, combined immunotherapy, and minimal residual disease clearance. This probe achieves integrated diagnosis and treatment, possessing high activity, high targeting, and low toxicity, showing excellent prospects for clinical translation.

This application provides a method, system, device, medium, and program product for analyzing bone marrow metastases in neuroblastoma, relating to the fields of intelligent medical image analysis and artificial intelligence-assisted diagnosis. The application includes: obtaining digitized whole-slice images of bone marrow cells from bone marrow cytological smears and preprocessing these images; preprocessing the whole-slice images to obtain bone marrow cell image blocks; weighting the bone marrow cell image blocks to obtain bone marrow cell feature images; wherein, the weighting processing includes feature extraction from the bone marrow cell image blocks to obtain corresponding feature vectors, employing multi-instance learning to represent the feature vectors at the whole-slice level to obtain bone marrow cell feature images; and classifying the bone marrow cell feature images to obtain corresponding classification results. This application achieves effective fusion from local cytological features to whole-slice-level diagnostic results through a multi-instance learning aggregation module.

Macromolecular prodrugs are provided in which 7-hydroxymethyl camptothecin (CPT-MeOH) is covalently bonded to a polymer through an ester linkage that is unstable under physiological conditions. The CPT-MeOH can be functionalized with a norepinephrine transporter (NET) ligand. Methods of treating cancer, particularly neuroblastoma, with the macromolecular prodrugs are also provided.